Prospective Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Jun 21, 2023; 29(23): 3703-3714
Published online Jun 21, 2023. doi: 10.3748/wjg.v29.i23.3703
Table 1 Patients’ characteristics
Patients’ characteristics
n = 107
M/F61/46
Age (yr)55.1 ± 15.9
BMI (kg/m2)26.8 ± 4.1
Metabolic diseases
    Diabetes mellitus (yes/no)25/82
    Dyslipidemia (yes/no)35/72
    Hypertension (yes/no)37/70
Concomitant drugs
    SGLT2 inhibitor12
    DPP-4 inhibitor13
    Thiazolidinedione2
    GLP-1 agonist2
    Statin19
    Bezafibrate0
    Pemafibrate8
    EPA and DHA preparation1
AST (U/L)44.9 ± 38.0
ALT (U/L)70.6 ± 57.7
GGT (U/L)99.6 ± 139.7
T-B (mg/dL)0.9 ± 0.5
Alb (mg/dL)4.5 ± 0.4
eGFR (mL/min)73.0 ± 15.0
HbA1c (%)6.5 ± 1.2
T-chol (mg/dL)202.1 ± 52.6
TG (mg/dL)180.0 ± 119.0
WBC (103/μL)6731.8 ± 1882.5
Hb (g/dL)14.7 ± 1.3
Plts (104/μL)23.9 ± 7.6
Fib-4 index1.53 ± 1.90
Table 2 Comparison of the two groups classified by area of non-alcoholic steatohepatitis pentagon

Large pentagon group (n = 64)
Small pentagon group (n = 43)
P value
M/F33/3128/150.165
Age (yr)60.8 ± 15.246.4 ± 13.2< 0.0001
Metabolic diseases
    Diabetes mellitus (yes/no)18/466/370.0849
    Dyslipidemia (yes/no)27/378/350.0108
    Hypertension (yes/no)29/357/360.0183
AST (U/L)52.6 ± 44.240.3 ± 24.40.0521
ALT (U/L)61.1 ± 45.283.0 ± 71.60.1699
GGT (U/L)97.3 ± 123.2102.9 ± 162.00.7238
T-B (mg/dL)1.01 ± 0.60.77 ± 0.30.0044
Alb (mg/dL)4.5 ± 0.44.6 ± 0.40.2843
eGFR (mL/min)71.8 ± 16.474.7 ± 12.10.1639
HbA1c (%)6.5 ± 1.16.3 ± 1.20.2847
T-chol (mg/dL)188.5 ± 59.4221.3 ± 33.80.008
TG (mg/dL)172.9 ± 126.5189.9 ± 108.80.1278
WBC (103/μL)6225.0 ± 1586.97463.9 ± 2050.90.008
Hb (g/dL)14.7 ± 1.314.7 ± 1.50.6836
Plts (104/μL)21.0 ± 6.528.8 ± 6.6< 0.0001
SWS (m/s)1.78 ± 0.361.39 ± 0.14< 0.0001
DS [(m/s)/kHz]13.3 ± 3.710.8 ± 2.0< 0.0001
ATI value [(dB/cm)/MHz]0.78 ± 0.130.74 ± 0.130.1047
Fib-4 index2.2 ± 2.30.7 ± 0.4< 0.0001
BMI (kg/m2)27.8 ± 4.425.6 ± 3.20.0249
NASH/NAFL22/423/400.0042